Applying clinical decision aids for the assessment and management of febrile infants presenting to emergency care in the UK and Ireland: Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study protocol.
Epidemiology
Paediatric A&E and ambulatory care
Paediatric infectious disease & immunisation
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
20 09 2023
20 09 2023
Historique:
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
Febrile infants 90 days and younger are at risk of invasive bacterial infections (bacteraemia and meningitis) and urinary tract infections. Together this is previously termed serious bacterial infection with an incidence of approximately 10-20%. The National Institute for Health and Care Excellence guidance advocates a cautious approach with most infants requiring septic screening, parenteral broad-spectrum antibiotics and hospital admission. Internationally, variations exist in the approach to febrile infants, with European and North American guidance advocating a tailored approach based on clinical features and biomarker testing. None of the available international clinical decision aids (CDAs) has been validated in the UK and Irish cohorts. The aim of the Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study is to prospectively validate a range of CDAs in a UK and Irish population including CDAs that use procalcitonin testing. The FIDO Study is a prospective multicentre mixed-methods cohort study conducted in UK and Irish hospitals. All infants aged 90 days and younger presenting with fever or history of fever (≥38°C) are eligible for inclusion. Infants will receive standard emergency clinical care without delay. Clinical data and blood samples will be collected, and consent will be obtained at the earliest appropriate opportunity using research without prior consent methodology. The performance and cost-effectiveness of CDAs will be assessed. An embedded qualitative study will explore clinician and caregiver views on different approaches to care and perceptions of risk. This study was reviewed and approved by the Office for Research Ethics Committees Northern Ireland-Health and Social Care Research Ethics Committee B, Public Benefit and Privacy Panel for Health and Social Care Scotland, and Children's Health Ireland Research and Ethics Committee Ireland. The results of this study will be presented at academic conferences and in peer-reviewed publications. NCT05259683.
Identifiants
pubmed: 37730397
pii: bmjopen-2023-075823
doi: 10.1136/bmjopen-2023-075823
pmc: PMC10514651
doi:
Banques de données
ClinicalTrials.gov
['NCT05259683']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e075823Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Chem. 2003 Jan;49(1):7-18
pubmed: 12507954
Pediatrics. 2022 Jun 1;149(6):
pubmed: 35578916
Lancet. 2019 May 25;393(10186):2125-2134
pubmed: 31005385
Pharmacoeconomics. 2008;26(9):781-98
pubmed: 18767898
Pediatrics. 2016 Aug;138(2):
pubmed: 27382134
JAMA Pediatr. 2019 Apr 1;173(4):342-351
pubmed: 30776077
Pharmacoeconomics. 2008;26(9):799-806
pubmed: 18767899
Pediatr Emerg Care. 2017 Nov;33(11):748-753
pubmed: 29095773
BMC Med. 2022 Jan 12;20(1):23
pubmed: 35022047
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Arch Dis Child Educ Pract Ed. 2016 Feb;101(1):49-53
pubmed: 26464416
Pharmacoeconomics. 2006;24(4):355-71
pubmed: 16605282
Arch Dis Child. 2019 Oct;104(10):979-983
pubmed: 31175126
JAC Antimicrob Resist. 2021 Mar 12;3(1):dlab029
pubmed: 34223103
Arch Dis Child. 2022 Apr;107(4):329-334
pubmed: 34531196
BMC Med. 2015 Jan 06;13:1
pubmed: 25563062
BMC Med. 2019 Mar 6;17(1):48
pubmed: 30836976
PLoS One. 2010 Aug 27;5(8):e12448
pubmed: 20805983
Pediatrics. 2018 Dec;142(6):
pubmed: 30425130
Pediatrics. 2021 Aug;148(2):
pubmed: 34281996
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970
Lancet Infect Dis. 2021 Apr;21(4):569-577
pubmed: 33186517